Biocon Biologics Secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company, announced a settlement and license agreement with Regeneron that clears the way to commercialize Yesafili™ (aflibercept-jbvf), an interchangeable biosimilar aflibercept, in the United States. The agreement enables the Company to launch in the United States in the second half of calendar year 2026 or earlier in certain circumstances. Yesafili™ is intended for the treatment of several different types of ophthalmology conditions and is highly similar to the reference product Eylea® (aflibercept). The approval for Yesafili™ was based on a comprehensive package of analytical, nonclinical and clinical data.